Launch of 20 new medicines expected by 2030
Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios
Investing in disruptive innovation that will shape the future of medicine and drive long-term growth
Decoupling carbon emissions from revenue growth
(BUSI…